Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 373,252
  • Shares Outstanding, K 53,398
  • Annual Sales, $ 0 K
  • Annual Income, $ -93,670 K
  • 60-Month Beta 1.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.84
Trade EVLO with:

Options Overview

Details
  • Implied Volatility 242.97%
  • Historical Volatility 117.59%
  • IV Percentile 94%
  • IV Rank 80.20%
  • IV High 280.03% on 08/19/21
  • IV Low 92.92% on 04/08/21
  • Put/Call Vol Ratio 1.35
  • Today's Volume 1,303
  • Volume Avg (30-Day) 866
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 3,701
  • Open Int (30-Day) 2,746

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.53
  • Number of Estimates 3
  • High Estimate -0.45
  • Low Estimate -0.60
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.67 +9.59%
on 09/14/21
11.56 -36.79%
on 09/01/21
-2.43 (-24.95%)
since 08/16/21
3-Month
6.67 +9.59%
on 09/14/21
17.13 -57.31%
on 06/23/21
-8.82 (-54.68%)
since 06/16/21
52-Week
3.82 +91.36%
on 10/30/20
19.93 -63.32%
on 01/28/21
+2.38 (+48.28%)
since 09/16/20

Most Recent Stories

More News
Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new type of orally delivered medicines, today announced that the U.S. Patent and Trademark Office has issued a...

EVLO : 7.31 (+4.58%)
Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options

Investors need to pay close attention to Evelo Biosciences (EVLO) stock based on the movements in the options market lately.

EVLO : 7.31 (+4.58%)
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D.,...

EVLO : 7.31 (+4.58%)
Are Options Traders Betting on a Big Move in Evelo (EVLO) Stock?

Investors need to pay close attention to Evelo (EVLO) stock based on the movements in the options market lately.

EVLO : 7.31 (+4.58%)
Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights

-EDP1815 Phase 2b data in psoriasis expected in 3Q 2021-

EVLO : 7.31 (+4.58%)
Anavex (AVXL) to Report Q3 Earning: What's in the Cards?

On Anavex's (AVXL) earnings call for the fiscal third quarter, investor focus will mainly be on the company's progress with its lead investigational candidate for Alzheimer's disease.

AVXL : 16.97 (-0.59%)
CTMX : 5.06 (+1.81%)
CRVS : 2.26 (-1.31%)
EVLO : 7.31 (+4.58%)
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at...

EVLO : 7.31 (+4.58%)
Evelo Biosciences Announces Grant of Inducement Award

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on July 12, 2021, Ayse Kocak commenced her services...

EVLO : 7.31 (+4.58%)
Evelo Biosciences Announces Grant of Inducement Award

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on June 14, 2021, Mark Plinio commenced his services...

EVLO : 7.31 (+4.58%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 13.07 (+2.75%)
SANA : 25.71 (-0.66%)
SGTX : 6.08 (+5.74%)
AXLA : 3.24 (+1.25%)
CDAK : 19.14 (+6.16%)
EVLO : 7.31 (+4.58%)
KLDO : 5.45 (+1.30%)
MRNA : 440.65 (+1.42%)
RUBY : 20.30 (+1.50%)
MCRB : 6.51 (+2.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 8.37
2nd Resistance Point 7.99
1st Resistance Point 7.65
Last Price 7.31
1st Support Level 6.93
2nd Support Level 6.55
3rd Support Level 6.21

See More

52-Week High 19.93
Fibonacci 61.8% 13.77
Fibonacci 50% 11.87
Fibonacci 38.2% 9.97
Last Price 7.31
52-Week Low 3.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar